Amgen's results for Q3 2026 (quarter ended Sep 30, 2026) come from the company's own earnings release, filed with the SEC on 2026-11-03. Everything below is taken from that filing; quotes are copied exactly. Company outlooks are the company's own.
At a glance
| Item | Value |
|---|---|
| Revenue (GAAP) | $10,365 million (+8.4% vs a year earlier) |
| Diluted EPS (GAAP) | $7.08 |
| Adjusted per-share figure (company's non-GAAP measure; FFO/AFFO for REITs) | $6.45 |
| Full-year guidance | Stated (no change given) |
Guidance
Amgen expects FY2026 total revenues of $38.9–39.7 billion, GAAP EPS of $18.34–19.28 and non-GAAP EPS of $22.90–23.70.
Why this label: '2026 Guidance' lists revenue $38.9-$39.7B and EPS ranges with no prior figures or change wording; mid-year guide, not called initial.
| Metric | Period | New | Prior (as stated in the release) |
|---|---|---|---|
| total revenues | FY2026 | $38.9–39.7 billion | not stated |
| GAAP EPS | FY2026 | $18.34–19.28 | not stated |
| non-GAAP EPS | FY2026 | $22.90–23.70 | not stated |
| capital expenditures | FY2026 | approximately $2.6 billion | not stated |
| share repurchases | FY2026 | not to exceed $3.0 billion | not stated |
From the release
Revenue: "Total revenues · 10,365 · 9,557"
Earnings per share: "Diluted EPS · $ · 7.08 · $ · 6.45 · $ · 5.93 · $ · 5.64"
total revenues: "Total revenues in the range of $38.9 billion to $39.7 billion."
GAAP EPS: "On a GAAP basis, EPS in the range of $18.34 to $19.28, and a tax rate in the range of 14.5% to 16.0%."
non-GAAP EPS: "On a non-GAAP basis, EPS in the range of $22.90 to $23.70, and a tax rate in the range of 15.0% to 16.5%."
Quotes are copied from the filing; in table rows, cell borders are shown as “·”.
Key fact: Q3 total revenues rose 8% to $10.4 billion; non-GAAP EPS up 14% to $6.45.
Source
Amgen earnings release (SEC filing), accession 0000318154-26-000153, filed 2026-11-03.
Part of the Q3 2026 Guidance Tracker. Educational only, not advice. Free weekly recap every Sunday: yieldterminalpro.com/newsletter.